197 related articles for article (PubMed ID: 20204543)
1. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
Ni LN; Li JY; Miao KR; Qiao C; Zhang SJ; Qiu HR; Qian SX
Med Oncol; 2011 Mar; 28(1):265-9. PubMed ID: 20204543
[TBL] [Abstract][Full Text] [Related]
2. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
3. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Dulucq S; Bouchet S; Turcq B; Lippert E; Etienne G; Reiffers J; Molimard M; Krajinovic M; Mahon FX
Blood; 2008 Sep; 112(5):2024-7. PubMed ID: 18524988
[TBL] [Abstract][Full Text] [Related]
5. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia.
Chhikara S; Sazawal S; Mishra P; Chaubey R; Mahapatra M; Saxena R
Natl Med J India; 2015; 28(6):272-5. PubMed ID: 27294449
[TBL] [Abstract][Full Text] [Related]
6. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
8. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
Ali MA; Elsalakawy WA
Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
[TBL] [Abstract][Full Text] [Related]
9. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract][Full Text] [Related]
11. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
12. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
[TBL] [Abstract][Full Text] [Related]
13. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis.
Zu B; Li Y; Wang X; He D; Huang Z; Feng W
Pharmacogenomics; 2014 Apr; 15(5):667-77. PubMed ID: 24798723
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
Vine J; Cohen SB; Ruchlemer R; Goldschmidt N; Levin M; Libster D; Gural A; Gatt ME; Lavie D; Ben-Yehuda D; Rund D
Leuk Lymphoma; 2014 Nov; 55(11):2525-31. PubMed ID: 24524306
[TBL] [Abstract][Full Text] [Related]
15. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
16. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.
Maffioli M; Camós M; Gaya A; Hernández-Boluda JC; Alvarez-Larrán A; Domingo A; Granell M; Guillem V; Vallansot R; Costa D; Bellosillo B; Colomer D; Cervantes F
Leuk Res; 2011 Aug; 35(8):1014-9. PubMed ID: 21185600
[TBL] [Abstract][Full Text] [Related]
17. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.
Koren-Michowitz M; Buzaglo Z; Ribakovsky E; Schwarz M; Pessach I; Shimoni A; Beider K; Amariglio N; le Coutre P; Nagler A
Eur J Haematol; 2014 Apr; 92(4):283-8. PubMed ID: 24215657
[TBL] [Abstract][Full Text] [Related]
18. Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Kassogue Y; Quachouh M; Dehbi H; Quessar A; Benchekroun S; Nadifi S
Med Oncol; 2014 Jan; 31(1):782. PubMed ID: 24293093
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia.
Wang JL; Liu HJ; Li F; Yang WY; Wang JM; Tan SF; Wang Q
Genet Mol Res; 2015 Nov; 14(4):14967-78. PubMed ID: 26634458
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients.
Au A; Baba AA; Azlan H; Norsa'adah B; Ankathil R
J Clin Pharm Ther; 2014 Dec; 39(6):685-90. PubMed ID: 25060527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]